Cellebrite Thomas Hogan Sells 103K Shares: Investor Outlook
Cellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
Timing matters: restructuring is best when income changes or spending diverges from goals.
16,677 articlesCellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
IBM faced a tough earnings moment that rattled investors. This deep-dive breaks down dividend safety, what those numb...
LRI Investments disclosed a sizable purchase of VBIL, the Vanguard 0-3 Month Treasury Bill ETF, worth about $16 milli...
Tesla stock has dipped below $400 again, prompting questions about a potential buy. This guide weighs growth drivers ...
Is Occidental Petroleum a smart move for your portfolio in 2026? This guide breaks down the debt story, cash flow, an...
A major bet from a savvy institutional investor puts Brookdale Senior Living in the spotlight. Mason Capital Manageme...
Constellation Energy plunged today after a mix of macro moves and strategic shifts. This guide breaks down the factor...
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
When a tech titan speaks, markets listen. This article breaks down NVIDIA's latest signals from the GTC AI conference...
Quadrant Private Wealth recently boosted its stake in Bluerock Private Real Estate Fund by about $13.6 million. This ...
MSGM's Q1 2026 commentary offers a clearer view of the year ahead for investors. This article decodes the msgm 2026 e...
JPMorgan Chase has built a long runway of dividend growth, but is it the best dividend stock in banking for your port...